METTL2A

Across TCGA pan-cancer cohorts, METTL2A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated METTL2A data layer compared with 29 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher METTL2A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated METTL2A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, BLCA, and SKCM are the cancer types where METTL2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.090	0.812	<.001	24	view →
BLCA	OS	Median	III,IV	0.085	0.684	<.001	24	view →
SKCM	DFS	Median	All	0.177	0.616	.001	20	view →
UCEC	DFS	Median	All	1.000	0.830	.030	6	view →
LIHC	OS	Median	All	0.169	0.669	.032	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

METTL2A–LUAD (OS)

Open the LUAD breakdown →